​

Inhibrx Biosciences (INBX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

INBX Stock Rating

Inhibrx Biosciences stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (60.00%), 2 Hold (40.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 2 3 Strong Sell Sell Hold Buy Strong Buy

INBX Price Target Upside V Benchmarks

TypeNameUpside
StockInhibrx Biosciences-
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$14.33$14.33$14.33
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25--2--2
May, 25--2--2
Apr, 25--2--2
Mar, 25--2--2
Feb, 25--2--2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 23, 2024JMP SecuritiesOutperformMarket Performinitialise
Aug 23, 2023JMP SecuritiesOutperformOutperformhold

Financial Forecast

EPS Forecast

$-50 $-10 $30 $70 $110 $150 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.99$-2.15$-3.62$-5.12$114.01----
Avg Forecast$-2.64$-2.16$-3.36$-4.39$-5.87$-6.17$-5.04$-2.43$-3.40
High Forecast$-2.64$-2.16$-3.36$-4.29$-5.87$-6.17$-5.04$-2.43$-3.40
Low Forecast$-2.64$-2.16$-3.36$-4.49$-5.87$-6.17$-5.04$-2.43$-3.40
Surprise %13.26%-0.46%7.74%16.63%-2042.25%----

Revenue Forecast

$0 $70M $140M $210M $280M $350M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$12.81M$7.13M$2.18M$1.80M$200.00K----
Avg Forecast$11.10M$6.10M$2.60M$250.00K$250.00K$2.00M$121.96M$337.85M$346.75M
High Forecast$11.10M$6.10M$2.60M$250.00K$250.00K$2.00M$121.96M$337.85M$346.75M
Low Forecast$11.10M$6.10M$2.60M$250.00K$250.00K$2.00M$121.96M$337.85M$346.75M
Surprise %15.39%16.80%-16.23%620.00%-20.00%----

Net Income Forecast

$-500M $0 $500M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-75.64M$-81.77M$-145.23M$-241.36M$1.69B----
Avg Forecast$-124.31M$-84.59M$-97.33M$-271.15M$-276.42M$-290.79M$-237.54M$-114.53M$-160.24M
High Forecast$-124.31M$-67.67M$-77.87M$-216.92M$-276.42M$-290.79M$-237.54M$-114.53M$-160.24M
Low Forecast$-124.31M$-101.50M$-116.80M$-325.39M$-276.42M$-290.79M$-237.54M$-114.53M$-160.24M
Surprise %-39.15%-3.33%49.21%-10.99%-710.52%----

INBX Forecast FAQ

Is Inhibrx Biosciences stock a buy?

Inhibrx Biosciences stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Inhibrx Biosciences is a favorable investment for most analysts.

What is Inhibrx Biosciences's price target?

Inhibrx Biosciences's price target, set by 5 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $14.33.

How does Inhibrx Biosciences stock forecast compare to its benchmarks?

Inhibrx Biosciences's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (24.81%) and underperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for Inhibrx Biosciences over the past three months?

  • June 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 0% Strong Buy, 0% Buy, 100.00% Hold, 0% Sell, 0% Strong Sell.

What is Inhibrx Biosciences’s EPS forecast?

Inhibrx Biosciences's average annual EPS forecast for its fiscal year ending in December 2025 is $-6.17, marking a -105.41% decrease from the reported $114.01 in 2024. Estimates for the following years are $-5.04 in 2026, $-2.43 in 2027, and $-3.4 in 2028.

What is Inhibrx Biosciences’s revenue forecast?

Inhibrx Biosciences's average annual revenue forecast for its fiscal year ending in December 2025 is $2M, reflecting a 897.50% increase from the reported $200K in 2024. The forecast for 2026 is $121.96M, followed by $337.85M for 2027, and $346.76M for 2028.

What is Inhibrx Biosciences’s net income forecast?

Inhibrx Biosciences's net income forecast for the fiscal year ending in December 2025 stands at $-291M, representing a -117.23% decrease from the reported $1.69B in 2024. Projections indicate $-238M in 2026, $-115M in 2027, and $-160M in 2028.